nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—H1F0—hematologic cancer	0.315	0.906	CbGaD
Aripiprazole—ABCB1—hematologic cancer	0.0326	0.0936	CbGaD
Aripiprazole—ABCB1—Lenalidomide—hematologic cancer	0.00978	0.0317	CbGbCtD
Aripiprazole—CYP3A7—Ifosfamide—hematologic cancer	0.00941	0.0305	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.00941	0.0305	CbGbCtD
Aripiprazole—CYP3A7—Imatinib—hematologic cancer	0.00899	0.0292	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.00899	0.0292	CbGbCtD
Aripiprazole—CYP3A5—Daunorubicin—hematologic cancer	0.00881	0.0286	CbGbCtD
Aripiprazole—CYP2D6—Lomustine—hematologic cancer	0.00856	0.0278	CbGbCtD
Aripiprazole—CYP3A5—Thalidomide—hematologic cancer	0.00802	0.026	CbGbCtD
Aripiprazole—CYP3A5—Teniposide—hematologic cancer	0.00765	0.0248	CbGbCtD
Aripiprazole—CYP2D6—Idarubicin—hematologic cancer	0.00763	0.0248	CbGbCtD
Aripiprazole—CYP3A5—Ifosfamide—hematologic cancer	0.00706	0.0229	CbGbCtD
Aripiprazole—CYP3A5—Imatinib—hematologic cancer	0.00675	0.0219	CbGbCtD
Aripiprazole—CYP2D6—Hydroxyurea—hematologic cancer	0.00649	0.021	CbGbCtD
Aripiprazole—CYP3A4—Bexarotene—hematologic cancer	0.00586	0.019	CbGbCtD
Aripiprazole—ABCB1—Daunorubicin—hematologic cancer	0.00573	0.0186	CbGbCtD
Aripiprazole—CYP2D6—Bortezomib—hematologic cancer	0.00565	0.0183	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00562	0.0182	CbGbCtD
Aripiprazole—CYP3A7—Irinotecan—hematologic cancer	0.00562	0.0182	CbGbCtD
Aripiprazole—ABCB1—Alitretinoin—hematologic cancer	0.00562	0.0182	CbGbCtD
Aripiprazole—CYP3A4—Lomustine—hematologic cancer	0.00545	0.0177	CbGbCtD
Aripiprazole—CYP3A4—Busulfan—hematologic cancer	0.00545	0.0177	CbGbCtD
Aripiprazole—CYP3A5—Dasatinib—hematologic cancer	0.00542	0.0176	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00491	0.0159	CbGbCtD
Aripiprazole—CYP3A7—Vincristine—hematologic cancer	0.00491	0.0159	CbGbCtD
Aripiprazole—CYP3A4—Thiotepa—hematologic cancer	0.00485	0.0157	CbGbCtD
Aripiprazole—ABCB1—Imatinib—hematologic cancer	0.00439	0.0142	CbGbCtD
Aripiprazole—CYP3A5—Irinotecan—hematologic cancer	0.00421	0.0137	CbGbCtD
Aripiprazole—CYP2D6—Imatinib—hematologic cancer	0.00414	0.0134	CbGbCtD
Aripiprazole—ABCB1—Nilotinib—hematologic cancer	0.00399	0.0129	CbGbCtD
Aripiprazole—ABCB1—Vinorelbine—hematologic cancer	0.00396	0.0128	CbGbCtD
Aripiprazole—CYP3A4—Methoxsalen—hematologic cancer	0.00377	0.0122	CbGbCtD
Aripiprazole—CYP2D6—Nilotinib—hematologic cancer	0.00376	0.0122	CbGbCtD
Aripiprazole—CYP2D6—Vinorelbine—hematologic cancer	0.00373	0.0121	CbGbCtD
Aripiprazole—CYP3A7—Dexamethasone—hematologic cancer	0.0037	0.012	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.0037	0.012	CbGbCtD
Aripiprazole—CYP3A5—Vincristine—hematologic cancer	0.00368	0.0119	CbGbCtD
Aripiprazole—CYP3A4—Bortezomib—hematologic cancer	0.00359	0.0116	CbGbCtD
Aripiprazole—ABCB1—Dasatinib—hematologic cancer	0.00353	0.0114	CbGbCtD
Aripiprazole—ABCB1—Mitoxantrone—hematologic cancer	0.00348	0.0113	CbGbCtD
Aripiprazole—CYP3A4—Daunorubicin—hematologic cancer	0.00343	0.0111	CbGbCtD
Aripiprazole—CYP3A5—Etoposide—hematologic cancer	0.00338	0.0109	CbGbCtD
Aripiprazole—ABCB1—Betamethasone—hematologic cancer	0.0031	0.0101	CbGbCtD
Aripiprazole—ABCB1—Gemcitabine—hematologic cancer	0.00308	0.00998	CbGbCtD
Aripiprazole—ABCB1—Prednisolone—hematologic cancer	0.00306	0.00993	CbGbCtD
Aripiprazole—CYP3A4—Cytarabine—hematologic cancer	0.00303	0.00982	CbGbCtD
Aripiprazole—CYP3A4—Teniposide—hematologic cancer	0.00298	0.00967	CbGbCtD
Aripiprazole—ABCB1—Prednisone—hematologic cancer	0.00289	0.00938	CbGbCtD
Aripiprazole—CYP3A5—Dexamethasone—hematologic cancer	0.00277	0.009	CbGbCtD
Aripiprazole—CYP3A4—Ifosfamide—hematologic cancer	0.00275	0.00893	CbGbCtD
Aripiprazole—ABCB1—Irinotecan—hematologic cancer	0.00274	0.00889	CbGbCtD
Aripiprazole—CYP3A4—Imatinib—hematologic cancer	0.00263	0.00853	CbGbCtD
Aripiprazole—CYP3A4—Ruxolitinib—hematologic cancer	0.00248	0.00803	CbGbCtD
Aripiprazole—ABCB1—Vinblastine—hematologic cancer	0.00244	0.00791	CbGbCtD
Aripiprazole—ABCB1—Vincristine—hematologic cancer	0.0024	0.00777	CbGbCtD
Aripiprazole—CYP3A4—Nilotinib—hematologic cancer	0.00239	0.00775	CbGbCtD
Aripiprazole—CYP3A4—Vinorelbine—hematologic cancer	0.00237	0.00769	CbGbCtD
Aripiprazole—CYP2D6—Vinblastine—hematologic cancer	0.0023	0.00745	CbGbCtD
Aripiprazole—ABCB1—Cisplatin—hematologic cancer	0.00224	0.00725	CbGbCtD
Aripiprazole—ABCB1—Etoposide—hematologic cancer	0.0022	0.00712	CbGbCtD
Aripiprazole—CYP3A4—Triamcinolone—hematologic cancer	0.00217	0.00703	CbGbCtD
Aripiprazole—CYP3A4—Dasatinib—hematologic cancer	0.00211	0.00685	CbGbCtD
Aripiprazole—CYP3A4—Mitoxantrone—hematologic cancer	0.00209	0.00677	CbGbCtD
Aripiprazole—CYP3A4—Betamethasone—hematologic cancer	0.00186	0.00603	CbGbCtD
Aripiprazole—CYP3A4—Prednisolone—hematologic cancer	0.00184	0.00595	CbGbCtD
Aripiprazole—ABCB1—Dexamethasone—hematologic cancer	0.00181	0.00586	CbGbCtD
Aripiprazole—CYP3A4—Prednisone—hematologic cancer	0.00173	0.00562	CbGbCtD
Aripiprazole—CYP2D6—Dexamethasone—hematologic cancer	0.0017	0.00552	CbGbCtD
Aripiprazole—CYP3A4—Irinotecan—hematologic cancer	0.00164	0.00533	CbGbCtD
Aripiprazole—ABCB1—Doxorubicin—hematologic cancer	0.0015	0.00486	CbGbCtD
Aripiprazole—CYP3A4—Vinblastine—hematologic cancer	0.00146	0.00474	CbGbCtD
Aripiprazole—ABCB1—Methotrexate—hematologic cancer	0.00145	0.00471	CbGbCtD
Aripiprazole—CYP3A4—Vincristine—hematologic cancer	0.00144	0.00466	CbGbCtD
Aripiprazole—CYP2D6—Doxorubicin—hematologic cancer	0.00141	0.00458	CbGbCtD
Aripiprazole—CYP3A4—Etoposide—hematologic cancer	0.00132	0.00427	CbGbCtD
Aripiprazole—CYP3A4—Dexamethasone—hematologic cancer	0.00108	0.00351	CbGbCtD
Aripiprazole—DRD5—hematopoietic system—hematologic cancer	0.000913	0.0439	CbGeAlD
Aripiprazole—CYP3A4—Doxorubicin—hematologic cancer	0.000898	0.00291	CbGbCtD
Aripiprazole—Ziprasidone—H1F0—hematologic cancer	0.000882	0.857	CrCbGaD
Aripiprazole—DRD4—testis—hematologic cancer	0.00076	0.0365	CbGeAlD
Aripiprazole—H1F0—hematopoietic system—hematologic cancer	0.000707	0.034	CbGeAlD
Aripiprazole—HTR3A—hematopoietic system—hematologic cancer	0.000674	0.0324	CbGeAlD
Aripiprazole—CHRM4—testis—hematologic cancer	0.000574	0.0276	CbGeAlD
Aripiprazole—H1F0—gonad—hematologic cancer	0.000537	0.0258	CbGeAlD
Aripiprazole—SLC6A4—hematopoietic system—hematologic cancer	0.000514	0.0247	CbGeAlD
Aripiprazole—H1F0—blood—hematologic cancer	0.000468	0.0225	CbGeAlD
Aripiprazole—HTR1A—hematopoietic system—hematologic cancer	0.000456	0.0219	CbGeAlD
Aripiprazole—H1F0—bone marrow—hematologic cancer	0.000453	0.0218	CbGeAlD
Aripiprazole—HTR3A—blood—hematologic cancer	0.000447	0.0215	CbGeAlD
Aripiprazole—HTR7—hematopoietic system—hematologic cancer	0.000436	0.021	CbGeAlD
Aripiprazole—ADRA1A—hematopoietic system—hematologic cancer	0.000421	0.0202	CbGeAlD
Aripiprazole—H1F0—lung—hematologic cancer	0.00041	0.0197	CbGeAlD
Aripiprazole—KCNH2—hematopoietic system—hematologic cancer	0.000406	0.0195	CbGeAlD
Aripiprazole—HTR3A—lung—hematologic cancer	0.000391	0.0188	CbGeAlD
Aripiprazole—H1F0—testis—hematologic cancer	0.000387	0.0186	CbGeAlD
Aripiprazole—SLC6A4—blood—hematologic cancer	0.00034	0.0164	CbGeAlD
Aripiprazole—HTR2B—blood—hematologic cancer	0.000337	0.0162	CbGeAlD
Aripiprazole—CYP3A5—hematopoietic system—hematologic cancer	0.000335	0.0161	CbGeAlD
Aripiprazole—HTR7—gonad—hematologic cancer	0.000332	0.0159	CbGeAlD
Aripiprazole—HRH1—hematopoietic system—hematologic cancer	0.000326	0.0156	CbGeAlD
Aripiprazole—ADRA2A—hematopoietic system—hematologic cancer	0.00032	0.0154	CbGeAlD
Aripiprazole—ADRB1—lung—hematologic cancer	0.000309	0.0148	CbGeAlD
Aripiprazole—SLC6A4—lung—hematologic cancer	0.000298	0.0143	CbGeAlD
Aripiprazole—CHRM1—lung—hematologic cancer	0.000297	0.0143	CbGeAlD
Aripiprazole—HTR2B—lung—hematologic cancer	0.000296	0.0142	CbGeAlD
Aripiprazole—HTR7—blood—hematologic cancer	0.000289	0.0139	CbGeAlD
Aripiprazole—H1F0—lymph node—hematologic cancer	0.000281	0.0135	CbGeAlD
Aripiprazole—ADRA1A—blood—hematologic cancer	0.000279	0.0134	CbGeAlD
Aripiprazole—HTR2A—hematopoietic system—hematologic cancer	0.000272	0.0131	CbGeAlD
Aripiprazole—KCNH2—blood—hematologic cancer	0.000269	0.0129	CbGeAlD
Aripiprazole—ADRA2C—blood—hematologic cancer	0.000266	0.0128	CbGeAlD
Aripiprazole—KCNH2—bone marrow—hematologic cancer	0.00026	0.0125	CbGeAlD
Aripiprazole—HTR7—lung—hematologic cancer	0.000253	0.0122	CbGeAlD
Aripiprazole—CYP3A4—hematopoietic system—hematologic cancer	0.000252	0.0121	CbGeAlD
Aripiprazole—CHRM3—testis—hematologic cancer	0.000251	0.0121	CbGeAlD
Aripiprazole—CYP2D6—hematopoietic system—hematologic cancer	0.000248	0.0119	CbGeAlD
Aripiprazole—ADRA2A—gonad—hematologic cancer	0.000243	0.0117	CbGeAlD
Aripiprazole—DRD2—lung—hematologic cancer	0.000239	0.0115	CbGeAlD
Aripiprazole—HTR7—testis—hematologic cancer	0.000239	0.0115	CbGeAlD
Aripiprazole—ADRA2C—lung—hematologic cancer	0.000233	0.0112	CbGeAlD
Aripiprazole—DRD2—testis—hematologic cancer	0.000226	0.0109	CbGeAlD
Aripiprazole—KCNH2—testis—hematologic cancer	0.000223	0.0107	CbGeAlD
Aripiprazole—CYP3A5—blood—hematologic cancer	0.000222	0.0107	CbGeAlD
Aripiprazole—ADRA2C—testis—hematologic cancer	0.00022	0.0106	CbGeAlD
Aripiprazole—ADRA2A—blood—hematologic cancer	0.000212	0.0102	CbGeAlD
Aripiprazole—HTR2A—gonad—hematologic cancer	0.000207	0.00994	CbGeAlD
Aripiprazole—HTR2B—lymph node—hematologic cancer	0.000202	0.00972	CbGeAlD
Aripiprazole—CYP3A5—lung—hematologic cancer	0.000195	0.00936	CbGeAlD
Aripiprazole—HRH1—lung—hematologic cancer	0.000189	0.00909	CbGeAlD
Aripiprazole—ADRA2A—lung—hematologic cancer	0.000186	0.00893	CbGeAlD
Aripiprazole—HTR2A—blood—hematologic cancer	0.00018	0.00866	CbGeAlD
Aripiprazole—HRH1—testis—hematologic cancer	0.000178	0.00858	CbGeAlD
Aripiprazole—ABCB1—hematopoietic system—hematologic cancer	0.000178	0.00856	CbGeAlD
Aripiprazole—ADRA2A—testis—hematologic cancer	0.000175	0.00842	CbGeAlD
Aripiprazole—CYP3A4—blood—hematologic cancer	0.000167	0.00802	CbGeAlD
Aripiprazole—CYP2D6—blood—hematologic cancer	0.000164	0.00789	CbGeAlD
Aripiprazole—KCNH2—lymph node—hematologic cancer	0.000161	0.00776	CbGeAlD
Aripiprazole—ADRA2C—lymph node—hematologic cancer	0.000159	0.00765	CbGeAlD
Aripiprazole—HTR2A—lung—hematologic cancer	0.000158	0.00759	CbGeAlD
Aripiprazole—HTR2A—testis—hematologic cancer	0.000149	0.00716	CbGeAlD
Aripiprazole—CYP2D6—testis—hematologic cancer	0.000136	0.00652	CbGeAlD
Aripiprazole—ABCB1—gonad—hematologic cancer	0.000135	0.00651	CbGeAlD
Aripiprazole—HRH1—lymph node—hematologic cancer	0.000129	0.00622	CbGeAlD
Aripiprazole—ADRA2A—lymph node—hematologic cancer	0.000127	0.00611	CbGeAlD
Aripiprazole—ABCB1—blood—hematologic cancer	0.000118	0.00567	CbGeAlD
Aripiprazole—ABCB1—bone marrow—hematologic cancer	0.000114	0.00549	CbGeAlD
Aripiprazole—ABCB1—lung—hematologic cancer	0.000104	0.00497	CbGeAlD
Aripiprazole—ABCB1—testis—hematologic cancer	9.77e-05	0.00469	CbGeAlD
Aripiprazole—Nefazodone—ABCB1—hematologic cancer	7.66e-05	0.0744	CrCbGaD
Aripiprazole—Trazodone—ABCB1—hematologic cancer	7.09e-05	0.0688	CrCbGaD
Aripiprazole—ABCB1—lymph node—hematologic cancer	7.08e-05	0.0034	CbGeAlD
Aripiprazole—Cardiac disorder—Doxorubicin—hematologic cancer	6.68e-06	2.93e-05	CcSEcCtD
Aripiprazole—Flatulence—Epirubicin—hematologic cancer	6.67e-06	2.93e-05	CcSEcCtD
Aripiprazole—Tension—Epirubicin—hematologic cancer	6.64e-06	2.92e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Betamethasone—hematologic cancer	6.63e-06	2.91e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.63e-06	2.91e-05	CcSEcCtD
Aripiprazole—Dysgeusia—Epirubicin—hematologic cancer	6.63e-06	2.91e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Triamcinolone—hematologic cancer	6.59e-06	2.89e-05	CcSEcCtD
Aripiprazole—Nervousness—Epirubicin—hematologic cancer	6.58e-06	2.89e-05	CcSEcCtD
Aripiprazole—Back pain—Epirubicin—hematologic cancer	6.55e-06	2.87e-05	CcSEcCtD
Aripiprazole—Angiopathy—Doxorubicin—hematologic cancer	6.53e-06	2.87e-05	CcSEcCtD
Aripiprazole—Malaise—Methotrexate—hematologic cancer	6.52e-06	2.86e-05	CcSEcCtD
Aripiprazole—Dizziness—Etoposide—hematologic cancer	6.52e-06	2.86e-05	CcSEcCtD
Aripiprazole—Muscle spasms—Epirubicin—hematologic cancer	6.51e-06	2.86e-05	CcSEcCtD
Aripiprazole—Immune system disorder—Doxorubicin—hematologic cancer	6.5e-06	2.85e-05	CcSEcCtD
Aripiprazole—Vertigo—Methotrexate—hematologic cancer	6.5e-06	2.85e-05	CcSEcCtD
Aripiprazole—Mediastinal disorder—Doxorubicin—hematologic cancer	6.49e-06	2.85e-05	CcSEcCtD
Aripiprazole—Leukopenia—Methotrexate—hematologic cancer	6.48e-06	2.84e-05	CcSEcCtD
Aripiprazole—Chills—Doxorubicin—hematologic cancer	6.46e-06	2.83e-05	CcSEcCtD
Aripiprazole—Urticaria—Dexamethasone—hematologic cancer	6.44e-06	2.83e-05	CcSEcCtD
Aripiprazole—Urticaria—Betamethasone—hematologic cancer	6.44e-06	2.83e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.44e-06	2.83e-05	CcSEcCtD
Aripiprazole—Dizziness—Prednisolone—hematologic cancer	6.43e-06	2.82e-05	CcSEcCtD
Aripiprazole—Asthenia—Triamcinolone—hematologic cancer	6.41e-06	2.82e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Betamethasone—hematologic cancer	6.41e-06	2.81e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Betamethasone—hematologic cancer	6.41e-06	2.81e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Dexamethasone—hematologic cancer	6.41e-06	2.81e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Dexamethasone—hematologic cancer	6.41e-06	2.81e-05	CcSEcCtD
Aripiprazole—Nausea—Cisplatin—hematologic cancer	6.39e-06	2.81e-05	CcSEcCtD
Aripiprazole—Insomnia—Prednisone—hematologic cancer	6.39e-06	2.8e-05	CcSEcCtD
Aripiprazole—Vision blurred—Epirubicin—hematologic cancer	6.38e-06	2.8e-05	CcSEcCtD
Aripiprazole—Alopecia—Doxorubicin—hematologic cancer	6.36e-06	2.79e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Prednisone—hematologic cancer	6.34e-06	2.78e-05	CcSEcCtD
Aripiprazole—Pruritus—Triamcinolone—hematologic cancer	6.33e-06	2.78e-05	CcSEcCtD
Aripiprazole—Cough—Methotrexate—hematologic cancer	6.31e-06	2.77e-05	CcSEcCtD
Aripiprazole—Mental disorder—Doxorubicin—hematologic cancer	6.3e-06	2.77e-05	CcSEcCtD
Aripiprazole—Ill-defined disorder—Epirubicin—hematologic cancer	6.28e-06	2.76e-05	CcSEcCtD
Aripiprazole—Convulsion—Methotrexate—hematologic cancer	6.27e-06	2.75e-05	CcSEcCtD
Aripiprazole—Vomiting—Etoposide—hematologic cancer	6.27e-06	2.75e-05	CcSEcCtD
Aripiprazole—Malnutrition—Doxorubicin—hematologic cancer	6.26e-06	2.75e-05	CcSEcCtD
Aripiprazole—Erythema—Doxorubicin—hematologic cancer	6.26e-06	2.75e-05	CcSEcCtD
Aripiprazole—Anaemia—Epirubicin—hematologic cancer	6.26e-06	2.75e-05	CcSEcCtD
Aripiprazole—Agitation—Epirubicin—hematologic cancer	6.22e-06	2.73e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Prednisone—hematologic cancer	6.22e-06	2.73e-05	CcSEcCtD
Aripiprazole—Rash—Etoposide—hematologic cancer	6.22e-06	2.73e-05	CcSEcCtD
Aripiprazole—Dermatitis—Etoposide—hematologic cancer	6.21e-06	2.73e-05	CcSEcCtD
Aripiprazole—Headache—Etoposide—hematologic cancer	6.18e-06	2.71e-05	CcSEcCtD
Aripiprazole—Flatulence—Doxorubicin—hematologic cancer	6.17e-06	2.71e-05	CcSEcCtD
Aripiprazole—Arthralgia—Methotrexate—hematologic cancer	6.16e-06	2.7e-05	CcSEcCtD
Aripiprazole—Chest pain—Methotrexate—hematologic cancer	6.16e-06	2.7e-05	CcSEcCtD
Aripiprazole—Myalgia—Methotrexate—hematologic cancer	6.16e-06	2.7e-05	CcSEcCtD
Aripiprazole—Tension—Doxorubicin—hematologic cancer	6.15e-06	2.7e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Prednisone—hematologic cancer	6.14e-06	2.7e-05	CcSEcCtD
Aripiprazole—Dysgeusia—Doxorubicin—hematologic cancer	6.13e-06	2.69e-05	CcSEcCtD
Aripiprazole—Rash—Prednisolone—hematologic cancer	6.13e-06	2.69e-05	CcSEcCtD
Aripiprazole—Dermatitis—Prednisolone—hematologic cancer	6.12e-06	2.69e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	6.12e-06	2.68e-05	CcSEcCtD
Aripiprazole—Malaise—Epirubicin—hematologic cancer	6.11e-06	2.68e-05	CcSEcCtD
Aripiprazole—Fatigue—Prednisone—hematologic cancer	6.09e-06	2.67e-05	CcSEcCtD
Aripiprazole—Headache—Prednisolone—hematologic cancer	6.09e-06	2.67e-05	CcSEcCtD
Aripiprazole—Discomfort—Methotrexate—hematologic cancer	6.09e-06	2.67e-05	CcSEcCtD
Aripiprazole—Nervousness—Doxorubicin—hematologic cancer	6.08e-06	2.67e-05	CcSEcCtD
Aripiprazole—Vertigo—Epirubicin—hematologic cancer	6.08e-06	2.67e-05	CcSEcCtD
Aripiprazole—Syncope—Epirubicin—hematologic cancer	6.07e-06	2.66e-05	CcSEcCtD
Aripiprazole—Leukopenia—Epirubicin—hematologic cancer	6.06e-06	2.66e-05	CcSEcCtD
Aripiprazole—Back pain—Doxorubicin—hematologic cancer	6.06e-06	2.66e-05	CcSEcCtD
Aripiprazole—Constipation—Prednisone—hematologic cancer	6.04e-06	2.65e-05	CcSEcCtD
Aripiprazole—Muscle spasms—Doxorubicin—hematologic cancer	6.02e-06	2.64e-05	CcSEcCtD
Aripiprazole—Palpitations—Epirubicin—hematologic cancer	5.98e-06	2.63e-05	CcSEcCtD
Aripiprazole—Confusional state—Methotrexate—hematologic cancer	5.95e-06	2.61e-05	CcSEcCtD
Aripiprazole—Loss of consciousness—Epirubicin—hematologic cancer	5.95e-06	2.61e-05	CcSEcCtD
Aripiprazole—Dizziness—Triamcinolone—hematologic cancer	5.91e-06	2.6e-05	CcSEcCtD
Aripiprazole—Cough—Epirubicin—hematologic cancer	5.91e-06	2.59e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Methotrexate—hematologic cancer	5.9e-06	2.59e-05	CcSEcCtD
Aripiprazole—Vision blurred—Doxorubicin—hematologic cancer	5.9e-06	2.59e-05	CcSEcCtD
Aripiprazole—Convulsion—Epirubicin—hematologic cancer	5.87e-06	2.57e-05	CcSEcCtD
Aripiprazole—Infection—Methotrexate—hematologic cancer	5.87e-06	2.57e-05	CcSEcCtD
Aripiprazole—Nausea—Etoposide—hematologic cancer	5.86e-06	2.57e-05	CcSEcCtD
Aripiprazole—Hypertension—Epirubicin—hematologic cancer	5.85e-06	2.57e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Prednisone—hematologic cancer	5.82e-06	2.56e-05	CcSEcCtD
Aripiprazole—Asthenia—Dexamethasone—hematologic cancer	5.82e-06	2.55e-05	CcSEcCtD
Aripiprazole—Asthenia—Betamethasone—hematologic cancer	5.82e-06	2.55e-05	CcSEcCtD
Aripiprazole—Ill-defined disorder—Doxorubicin—hematologic cancer	5.81e-06	2.55e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Methotrexate—hematologic cancer	5.79e-06	2.54e-05	CcSEcCtD
Aripiprazole—Anaemia—Doxorubicin—hematologic cancer	5.79e-06	2.54e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Methotrexate—hematologic cancer	5.78e-06	2.54e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Prednisone—hematologic cancer	5.78e-06	2.54e-05	CcSEcCtD
Aripiprazole—Nausea—Prednisolone—hematologic cancer	5.77e-06	2.53e-05	CcSEcCtD
Aripiprazole—Chest pain—Epirubicin—hematologic cancer	5.76e-06	2.53e-05	CcSEcCtD
Aripiprazole—Arthralgia—Epirubicin—hematologic cancer	5.76e-06	2.53e-05	CcSEcCtD
Aripiprazole—Myalgia—Epirubicin—hematologic cancer	5.76e-06	2.53e-05	CcSEcCtD
Aripiprazole—Agitation—Doxorubicin—hematologic cancer	5.76e-06	2.53e-05	CcSEcCtD
Aripiprazole—Anxiety—Epirubicin—hematologic cancer	5.74e-06	2.52e-05	CcSEcCtD
Aripiprazole—Pruritus—Dexamethasone—hematologic cancer	5.74e-06	2.52e-05	CcSEcCtD
Aripiprazole—Pruritus—Betamethasone—hematologic cancer	5.74e-06	2.52e-05	CcSEcCtD
Aripiprazole—Skin disorder—Methotrexate—hematologic cancer	5.74e-06	2.52e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.72e-06	2.51e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Methotrexate—hematologic cancer	5.71e-06	2.51e-05	CcSEcCtD
Aripiprazole—Discomfort—Epirubicin—hematologic cancer	5.69e-06	2.5e-05	CcSEcCtD
Aripiprazole—Vomiting—Triamcinolone—hematologic cancer	5.68e-06	2.5e-05	CcSEcCtD
Aripiprazole—Malaise—Doxorubicin—hematologic cancer	5.65e-06	2.48e-05	CcSEcCtD
Aripiprazole—Rash—Triamcinolone—hematologic cancer	5.64e-06	2.47e-05	CcSEcCtD
Aripiprazole—Dry mouth—Epirubicin—hematologic cancer	5.64e-06	2.47e-05	CcSEcCtD
Aripiprazole—Dermatitis—Triamcinolone—hematologic cancer	5.63e-06	2.47e-05	CcSEcCtD
Aripiprazole—Vertigo—Doxorubicin—hematologic cancer	5.63e-06	2.47e-05	CcSEcCtD
Aripiprazole—Anorexia—Methotrexate—hematologic cancer	5.63e-06	2.47e-05	CcSEcCtD
Aripiprazole—Syncope—Doxorubicin—hematologic cancer	5.62e-06	2.47e-05	CcSEcCtD
Aripiprazole—Urticaria—Prednisone—hematologic cancer	5.61e-06	2.46e-05	CcSEcCtD
Aripiprazole—Leukopenia—Doxorubicin—hematologic cancer	5.61e-06	2.46e-05	CcSEcCtD
Aripiprazole—Headache—Triamcinolone—hematologic cancer	5.6e-06	2.46e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Prednisone—hematologic cancer	5.58e-06	2.45e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Prednisone—hematologic cancer	5.58e-06	2.45e-05	CcSEcCtD
Aripiprazole—Confusional state—Epirubicin—hematologic cancer	5.57e-06	2.45e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Betamethasone—hematologic cancer	5.55e-06	2.44e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Dexamethasone—hematologic cancer	5.55e-06	2.44e-05	CcSEcCtD
Aripiprazole—Palpitations—Doxorubicin—hematologic cancer	5.54e-06	2.43e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Epirubicin—hematologic cancer	5.53e-06	2.43e-05	CcSEcCtD
Aripiprazole—Oedema—Epirubicin—hematologic cancer	5.53e-06	2.43e-05	CcSEcCtD
Aripiprazole—Hypotension—Methotrexate—hematologic cancer	5.52e-06	2.42e-05	CcSEcCtD
Aripiprazole—Loss of consciousness—Doxorubicin—hematologic cancer	5.51e-06	2.42e-05	CcSEcCtD
Aripiprazole—Infection—Epirubicin—hematologic cancer	5.49e-06	2.41e-05	CcSEcCtD
Aripiprazole—Cough—Doxorubicin—hematologic cancer	5.47e-06	2.4e-05	CcSEcCtD
Aripiprazole—Shock—Epirubicin—hematologic cancer	5.44e-06	2.39e-05	CcSEcCtD
Aripiprazole—Convulsion—Doxorubicin—hematologic cancer	5.43e-06	2.38e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Epirubicin—hematologic cancer	5.42e-06	2.38e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Epirubicin—hematologic cancer	5.41e-06	2.37e-05	CcSEcCtD
Aripiprazole—Hypertension—Doxorubicin—hematologic cancer	5.41e-06	2.37e-05	CcSEcCtD
Aripiprazole—Tachycardia—Epirubicin—hematologic cancer	5.39e-06	2.37e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.38e-06	2.36e-05	CcSEcCtD
Aripiprazole—Skin disorder—Epirubicin—hematologic cancer	5.37e-06	2.36e-05	CcSEcCtD
Aripiprazole—Dizziness—Betamethasone—hematologic cancer	5.36e-06	2.35e-05	CcSEcCtD
Aripiprazole—Dizziness—Dexamethasone—hematologic cancer	5.36e-06	2.35e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Epirubicin—hematologic cancer	5.34e-06	2.34e-05	CcSEcCtD
Aripiprazole—Insomnia—Methotrexate—hematologic cancer	5.34e-06	2.34e-05	CcSEcCtD
Aripiprazole—Arthralgia—Doxorubicin—hematologic cancer	5.33e-06	2.34e-05	CcSEcCtD
Aripiprazole—Chest pain—Doxorubicin—hematologic cancer	5.33e-06	2.34e-05	CcSEcCtD
Aripiprazole—Myalgia—Doxorubicin—hematologic cancer	5.33e-06	2.34e-05	CcSEcCtD
Aripiprazole—Anxiety—Doxorubicin—hematologic cancer	5.31e-06	2.33e-05	CcSEcCtD
Aripiprazole—Nausea—Triamcinolone—hematologic cancer	5.31e-06	2.33e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Methotrexate—hematologic cancer	5.3e-06	2.33e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.3e-06	2.32e-05	CcSEcCtD
Aripiprazole—Discomfort—Doxorubicin—hematologic cancer	5.27e-06	2.31e-05	CcSEcCtD
Aripiprazole—Anorexia—Epirubicin—hematologic cancer	5.27e-06	2.31e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Methotrexate—hematologic cancer	5.26e-06	2.31e-05	CcSEcCtD
Aripiprazole—Somnolence—Methotrexate—hematologic cancer	5.25e-06	2.3e-05	CcSEcCtD
Aripiprazole—Dry mouth—Doxorubicin—hematologic cancer	5.22e-06	2.29e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Prednisone—hematologic cancer	5.21e-06	2.28e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Methotrexate—hematologic cancer	5.2e-06	2.28e-05	CcSEcCtD
Aripiprazole—Hypotension—Epirubicin—hematologic cancer	5.16e-06	2.27e-05	CcSEcCtD
Aripiprazole—Vomiting—Betamethasone—hematologic cancer	5.16e-06	2.26e-05	CcSEcCtD
Aripiprazole—Vomiting—Dexamethasone—hematologic cancer	5.16e-06	2.26e-05	CcSEcCtD
Aripiprazole—Confusional state—Doxorubicin—hematologic cancer	5.16e-06	2.26e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Methotrexate—hematologic cancer	5.13e-06	2.25e-05	CcSEcCtD
Aripiprazole—Rash—Betamethasone—hematologic cancer	5.12e-06	2.25e-05	CcSEcCtD
Aripiprazole—Rash—Dexamethasone—hematologic cancer	5.12e-06	2.25e-05	CcSEcCtD
Aripiprazole—Oedema—Doxorubicin—hematologic cancer	5.11e-06	2.24e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Doxorubicin—hematologic cancer	5.11e-06	2.24e-05	CcSEcCtD
Aripiprazole—Dermatitis—Dexamethasone—hematologic cancer	5.11e-06	2.24e-05	CcSEcCtD
Aripiprazole—Dermatitis—Betamethasone—hematologic cancer	5.11e-06	2.24e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.1e-06	2.24e-05	CcSEcCtD
Aripiprazole—Fatigue—Methotrexate—hematologic cancer	5.09e-06	2.23e-05	CcSEcCtD
Aripiprazole—Headache—Dexamethasone—hematologic cancer	5.08e-06	2.23e-05	CcSEcCtD
Aripiprazole—Headache—Betamethasone—hematologic cancer	5.08e-06	2.23e-05	CcSEcCtD
Aripiprazole—Infection—Doxorubicin—hematologic cancer	5.08e-06	2.23e-05	CcSEcCtD
Aripiprazole—Asthenia—Prednisone—hematologic cancer	5.07e-06	2.22e-05	CcSEcCtD
Aripiprazole—Pain—Methotrexate—hematologic cancer	5.05e-06	2.22e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.03e-06	2.21e-05	CcSEcCtD
Aripiprazole—Shock—Doxorubicin—hematologic cancer	5.03e-06	2.21e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Doxorubicin—hematologic cancer	5.01e-06	2.2e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Doxorubicin—hematologic cancer	5.01e-06	2.2e-05	CcSEcCtD
Aripiprazole—Pruritus—Prednisone—hematologic cancer	5e-06	2.19e-05	CcSEcCtD
Aripiprazole—Insomnia—Epirubicin—hematologic cancer	5e-06	2.19e-05	CcSEcCtD
Aripiprazole—Tachycardia—Doxorubicin—hematologic cancer	4.99e-06	2.19e-05	CcSEcCtD
Aripiprazole—Skin disorder—Doxorubicin—hematologic cancer	4.97e-06	2.18e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Epirubicin—hematologic cancer	4.96e-06	2.18e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Doxorubicin—hematologic cancer	4.94e-06	2.17e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Epirubicin—hematologic cancer	4.93e-06	2.16e-05	CcSEcCtD
Aripiprazole—Somnolence—Epirubicin—hematologic cancer	4.91e-06	2.16e-05	CcSEcCtD
Aripiprazole—Anorexia—Doxorubicin—hematologic cancer	4.87e-06	2.14e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Methotrexate—hematologic cancer	4.87e-06	2.14e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Epirubicin—hematologic cancer	4.86e-06	2.13e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Prednisone—hematologic cancer	4.83e-06	2.12e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Methotrexate—hematologic cancer	4.83e-06	2.12e-05	CcSEcCtD
Aripiprazole—Nausea—Betamethasone—hematologic cancer	4.82e-06	2.12e-05	CcSEcCtD
Aripiprazole—Nausea—Dexamethasone—hematologic cancer	4.82e-06	2.12e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Epirubicin—hematologic cancer	4.8e-06	2.11e-05	CcSEcCtD
Aripiprazole—Hypotension—Doxorubicin—hematologic cancer	4.78e-06	2.1e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.77e-06	2.09e-05	CcSEcCtD
Aripiprazole—Fatigue—Epirubicin—hematologic cancer	4.76e-06	2.09e-05	CcSEcCtD
Aripiprazole—Pain—Epirubicin—hematologic cancer	4.73e-06	2.07e-05	CcSEcCtD
Aripiprazole—Constipation—Epirubicin—hematologic cancer	4.73e-06	2.07e-05	CcSEcCtD
Aripiprazole—Urticaria—Methotrexate—hematologic cancer	4.69e-06	2.06e-05	CcSEcCtD
Aripiprazole—Dizziness—Prednisone—hematologic cancer	4.67e-06	2.05e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Methotrexate—hematologic cancer	4.67e-06	2.05e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Methotrexate—hematologic cancer	4.67e-06	2.05e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.66e-06	2.04e-05	CcSEcCtD
Aripiprazole—Insomnia—Doxorubicin—hematologic cancer	4.62e-06	2.03e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Doxorubicin—hematologic cancer	4.59e-06	2.02e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Doxorubicin—hematologic cancer	4.56e-06	2e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Epirubicin—hematologic cancer	4.55e-06	2e-05	CcSEcCtD
Aripiprazole—Somnolence—Doxorubicin—hematologic cancer	4.55e-06	1.99e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Epirubicin—hematologic cancer	4.52e-06	1.98e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Doxorubicin—hematologic cancer	4.5e-06	1.98e-05	CcSEcCtD
Aripiprazole—Vomiting—Prednisone—hematologic cancer	4.49e-06	1.97e-05	CcSEcCtD
Aripiprazole—Rash—Prednisone—hematologic cancer	4.45e-06	1.96e-05	CcSEcCtD
Aripiprazole—Dermatitis—Prednisone—hematologic cancer	4.45e-06	1.95e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Doxorubicin—hematologic cancer	4.44e-06	1.95e-05	CcSEcCtD
Aripiprazole—Headache—Prednisone—hematologic cancer	4.43e-06	1.94e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.41e-06	1.94e-05	CcSEcCtD
Aripiprazole—Fatigue—Doxorubicin—hematologic cancer	4.41e-06	1.93e-05	CcSEcCtD
Aripiprazole—Urticaria—Epirubicin—hematologic cancer	4.39e-06	1.93e-05	CcSEcCtD
Aripiprazole—Pain—Doxorubicin—hematologic cancer	4.37e-06	1.92e-05	CcSEcCtD
Aripiprazole—Constipation—Doxorubicin—hematologic cancer	4.37e-06	1.92e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Epirubicin—hematologic cancer	4.37e-06	1.92e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Epirubicin—hematologic cancer	4.37e-06	1.92e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Methotrexate—hematologic cancer	4.35e-06	1.91e-05	CcSEcCtD
Aripiprazole—Asthenia—Methotrexate—hematologic cancer	4.24e-06	1.86e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Doxorubicin—hematologic cancer	4.21e-06	1.85e-05	CcSEcCtD
Aripiprazole—Nausea—Prednisone—hematologic cancer	4.2e-06	1.84e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.18e-06	1.83e-05	CcSEcCtD
Aripiprazole—Pruritus—Methotrexate—hematologic cancer	4.18e-06	1.83e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Epirubicin—hematologic cancer	4.07e-06	1.79e-05	CcSEcCtD
Aripiprazole—Urticaria—Doxorubicin—hematologic cancer	4.06e-06	1.78e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Doxorubicin—hematologic cancer	4.04e-06	1.77e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Doxorubicin—hematologic cancer	4.04e-06	1.77e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Methotrexate—hematologic cancer	4.04e-06	1.77e-05	CcSEcCtD
Aripiprazole—Asthenia—Epirubicin—hematologic cancer	3.96e-06	1.74e-05	CcSEcCtD
Aripiprazole—Pruritus—Epirubicin—hematologic cancer	3.91e-06	1.72e-05	CcSEcCtD
Aripiprazole—Dizziness—Methotrexate—hematologic cancer	3.9e-06	1.71e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Epirubicin—hematologic cancer	3.78e-06	1.66e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Doxorubicin—hematologic cancer	3.77e-06	1.65e-05	CcSEcCtD
Aripiprazole—Vomiting—Methotrexate—hematologic cancer	3.75e-06	1.65e-05	CcSEcCtD
Aripiprazole—Rash—Methotrexate—hematologic cancer	3.72e-06	1.63e-05	CcSEcCtD
Aripiprazole—Dermatitis—Methotrexate—hematologic cancer	3.72e-06	1.63e-05	CcSEcCtD
Aripiprazole—Headache—Methotrexate—hematologic cancer	3.7e-06	1.62e-05	CcSEcCtD
Aripiprazole—Asthenia—Doxorubicin—hematologic cancer	3.67e-06	1.61e-05	CcSEcCtD
Aripiprazole—Dizziness—Epirubicin—hematologic cancer	3.65e-06	1.6e-05	CcSEcCtD
Aripiprazole—Pruritus—Doxorubicin—hematologic cancer	3.62e-06	1.59e-05	CcSEcCtD
Aripiprazole—Vomiting—Epirubicin—hematologic cancer	3.51e-06	1.54e-05	CcSEcCtD
Aripiprazole—Nausea—Methotrexate—hematologic cancer	3.51e-06	1.54e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Doxorubicin—hematologic cancer	3.5e-06	1.54e-05	CcSEcCtD
Aripiprazole—Rash—Epirubicin—hematologic cancer	3.48e-06	1.53e-05	CcSEcCtD
Aripiprazole—Dermatitis—Epirubicin—hematologic cancer	3.48e-06	1.53e-05	CcSEcCtD
Aripiprazole—Headache—Epirubicin—hematologic cancer	3.46e-06	1.52e-05	CcSEcCtD
Aripiprazole—Dizziness—Doxorubicin—hematologic cancer	3.38e-06	1.48e-05	CcSEcCtD
Aripiprazole—Nausea—Epirubicin—hematologic cancer	3.28e-06	1.44e-05	CcSEcCtD
Aripiprazole—Vomiting—Doxorubicin—hematologic cancer	3.25e-06	1.43e-05	CcSEcCtD
Aripiprazole—Rash—Doxorubicin—hematologic cancer	3.22e-06	1.41e-05	CcSEcCtD
Aripiprazole—Dermatitis—Doxorubicin—hematologic cancer	3.22e-06	1.41e-05	CcSEcCtD
Aripiprazole—Headache—Doxorubicin—hematologic cancer	3.2e-06	1.41e-05	CcSEcCtD
Aripiprazole—Nausea—Doxorubicin—hematologic cancer	3.04e-06	1.33e-05	CcSEcCtD
Aripiprazole—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	8.38e-07	8.91e-06	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—IL6—hematologic cancer	8.37e-07	8.91e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MAPK8—hematologic cancer	8.36e-07	8.9e-06	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—HRAS—hematologic cancer	8.36e-07	8.9e-06	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—IL6—hematologic cancer	8.36e-07	8.9e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	8.36e-07	8.9e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—hematologic cancer	8.35e-07	8.88e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—AKT1—hematologic cancer	8.34e-07	8.88e-06	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—PIK3CA—hematologic cancer	8.34e-07	8.87e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	8.34e-07	8.87e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ABCB1—hematologic cancer	8.32e-07	8.85e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	8.31e-07	8.85e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	8.31e-07	8.84e-06	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—IL6—hematologic cancer	8.31e-07	8.84e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EP300—hematologic cancer	8.31e-07	8.84e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	8.3e-07	8.83e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	8.29e-07	8.82e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL2—hematologic cancer	8.29e-07	8.82e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—hematologic cancer	8.26e-07	8.79e-06	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—HRAS—hematologic cancer	8.25e-07	8.78e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	8.24e-07	8.77e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MYC—hematologic cancer	8.24e-07	8.77e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	8.23e-07	8.76e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	8.22e-07	8.75e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	8.21e-07	8.73e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	8.21e-07	8.73e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MAPK3—hematologic cancer	8.2e-07	8.73e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MYC—hematologic cancer	8.2e-07	8.73e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	8.19e-07	8.71e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TGFB1—hematologic cancer	8.18e-07	8.7e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EP300—hematologic cancer	8.17e-07	8.7e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EP300—hematologic cancer	8.15e-07	8.68e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—EP300—hematologic cancer	8.15e-07	8.67e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	8.14e-07	8.66e-06	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—IL6—hematologic cancer	8.13e-07	8.65e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EP300—hematologic cancer	8.13e-07	8.65e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EP300—hematologic cancer	8.1e-07	8.62e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—PIK3CA—hematologic cancer	8.1e-07	8.62e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3R1—hematologic cancer	8.08e-07	8.6e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—NCOR1—hematologic cancer	8.08e-07	8.6e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GSTM1—hematologic cancer	8.08e-07	8.6e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	8.08e-07	8.59e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—SRC—hematologic cancer	8.08e-07	8.59e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MAPK3—hematologic cancer	8.07e-07	8.59e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CD—hematologic cancer	8.07e-07	8.58e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—JUN—hematologic cancer	8.06e-07	8.58e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—PIK3CA—hematologic cancer	8.03e-07	8.54e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EP300—hematologic cancer	8.02e-07	8.54e-06	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—IL6—hematologic cancer	8e-07	8.52e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EP300—hematologic cancer	8e-07	8.51e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—HRAS—hematologic cancer	7.98e-07	8.49e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MYC—hematologic cancer	7.98e-07	8.49e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KRAS—hematologic cancer	7.96e-07	8.47e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—ALB—hematologic cancer	7.96e-07	8.47e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TGFB1—hematologic cancer	7.96e-07	8.47e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—SRC—hematologic cancer	7.95e-07	8.46e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—SRC—hematologic cancer	7.93e-07	8.44e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—SRC—hematologic cancer	7.9e-07	8.41e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—HRAS—hematologic cancer	7.9e-07	8.41e-06	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—IL6—hematologic cancer	7.9e-07	8.4e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	7.89e-07	8.4e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—SRC—hematologic cancer	7.88e-07	8.38e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—hematologic cancer	7.87e-07	8.38e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—VEGFA—hematologic cancer	7.87e-07	8.37e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MYC—hematologic cancer	7.85e-07	8.35e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TGFB1—hematologic cancer	7.83e-07	8.33e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	7.81e-07	8.31e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—SRC—hematologic cancer	7.8e-07	8.3e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	7.8e-07	8.3e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—STAT3—hematologic cancer	7.79e-07	8.29e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—SRC—hematologic cancer	7.78e-07	8.28e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—NRAS—hematologic cancer	7.77e-07	8.27e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—hematologic cancer	7.77e-07	8.26e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	7.74e-07	8.24e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—VEGFA—hematologic cancer	7.72e-07	8.22e-06	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—AKT1—hematologic cancer	7.72e-07	8.22e-06	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—AKT1—hematologic cancer	7.71e-07	8.21e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	7.7e-07	8.19e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	7.67e-07	8.17e-06	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—AKT1—hematologic cancer	7.66e-07	8.15e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—STAT3—hematologic cancer	7.66e-07	8.15e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—STAT3—hematologic cancer	7.65e-07	8.14e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—NRAS—hematologic cancer	7.64e-07	8.13e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—IL6—hematologic cancer	7.64e-07	8.13e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—NRAS—hematologic cancer	7.63e-07	8.12e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	7.63e-07	8.11e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—STAT3—hematologic cancer	7.62e-07	8.11e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3R1—hematologic cancer	7.62e-07	8.1e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KRAS—hematologic cancer	7.62e-07	8.1e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	7.61e-07	8.09e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—NRAS—hematologic cancer	7.6e-07	8.09e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	7.6e-07	8.09e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—STAT3—hematologic cancer	7.6e-07	8.08e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—NRAS—hematologic cancer	7.58e-07	8.07e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	7.58e-07	8.06e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KRAS—hematologic cancer	7.58e-07	8.06e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—IL6—hematologic cancer	7.56e-07	8.05e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—HRAS—hematologic cancer	7.53e-07	8.01e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—STAT3—hematologic cancer	7.52e-07	8.01e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—NRAS—hematologic cancer	7.51e-07	7.99e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	7.5e-07	7.98e-06	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—AKT1—hematologic cancer	7.5e-07	7.98e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	7.49e-07	7.96e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CB—hematologic cancer	7.46e-07	7.94e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MAPK3—hematologic cancer	7.44e-07	7.92e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EP300—hematologic cancer	7.43e-07	7.91e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—HRAS—hematologic cancer	7.43e-07	7.9e-06	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—AKT1—hematologic cancer	7.38e-07	7.86e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KRAS—hematologic cancer	7.37e-07	7.84e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	7.32e-07	7.79e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	7.32e-07	7.78e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MAPK3—hematologic cancer	7.31e-07	7.77e-06	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—AKT1—hematologic cancer	7.28e-07	7.75e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	7.28e-07	7.75e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	7.26e-07	7.72e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KRAS—hematologic cancer	7.25e-07	7.72e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	7.25e-07	7.71e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MYC—hematologic cancer	7.24e-07	7.7e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—SRC—hematologic cancer	7.23e-07	7.69e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TGFB1—hematologic cancer	7.22e-07	7.68e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—IL6—hematologic cancer	7.21e-07	7.67e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	7.19e-07	7.65e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	7.17e-07	7.63e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PIK3CA—hematologic cancer	7.17e-07	7.63e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—MTHFR—hematologic cancer	7.14e-07	7.6e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MYC—hematologic cancer	7.12e-07	7.58e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—IL6—hematologic cancer	7.11e-07	7.56e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MYC—hematologic cancer	7.11e-07	7.56e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	7.1e-07	7.56e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TGFB1—hematologic cancer	7.09e-07	7.54e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MYC—hematologic cancer	7.08e-07	7.54e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—hematologic cancer	7.08e-07	7.53e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	7.07e-07	7.52e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MYC—hematologic cancer	7.06e-07	7.51e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—AKT1—hematologic cancer	7.05e-07	7.5e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	7.04e-07	7.49e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	7.04e-07	7.49e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CB—hematologic cancer	7.03e-07	7.48e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—hematologic cancer	7.01e-07	7.46e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	7e-07	7.45e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MYC—hematologic cancer	6.99e-07	7.44e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—AKT1—hematologic cancer	6.98e-07	7.42e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	6.97e-07	7.42e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MYC—hematologic cancer	6.97e-07	7.42e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	6.97e-07	7.42e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—PIK3CA—hematologic cancer	6.96e-07	7.41e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	6.96e-07	7.4e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	6.96e-07	7.4e-06	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—AKT1—hematologic cancer	6.81e-07	7.25e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—PIK3CA—hematologic cancer	6.77e-07	7.2e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—hematologic cancer	6.77e-07	7.2e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—HRAS—hematologic cancer	6.77e-07	7.2e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—hematologic cancer	6.73e-07	7.17e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	6.71e-07	7.14e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KRAS—hematologic cancer	6.69e-07	7.12e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—PIK3CA—hematologic cancer	6.66e-07	7.09e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	6.66e-07	7.09e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—AKT1—hematologic cancer	6.65e-07	7.07e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—AKT1—hematologic cancer	6.62e-07	7.04e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KRAS—hematologic cancer	6.58e-07	7e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PIK3CA—hematologic cancer	6.58e-07	7e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KRAS—hematologic cancer	6.57e-07	6.99e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—AKT1—hematologic cancer	6.56e-07	6.98e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—hematologic cancer	6.55e-07	6.97e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KRAS—hematologic cancer	6.54e-07	6.96e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KRAS—hematologic cancer	6.52e-07	6.94e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MYC—hematologic cancer	6.48e-07	6.89e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—IL6—hematologic cancer	6.48e-07	6.89e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—HRAS—hematologic cancer	6.47e-07	6.89e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	6.46e-07	6.88e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KRAS—hematologic cancer	6.46e-07	6.87e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTEN—hematologic cancer	6.45e-07	6.86e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—hematologic cancer	6.45e-07	6.86e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	6.44e-07	6.86e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—HRAS—hematologic cancer	6.44e-07	6.85e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—IL6—hematologic cancer	6.42e-07	6.83e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—HRAS—hematologic cancer	6.26e-07	6.67e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—IL6—hematologic cancer	6.2e-07	6.59e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—HRAS—hematologic cancer	6.17e-07	6.56e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—IL6—hematologic cancer	6.16e-07	6.56e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—EP300—hematologic cancer	6.15e-07	6.54e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	6.14e-07	6.54e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTEN—hematologic cancer	6.08e-07	6.46e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	6.05e-07	6.43e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	6.03e-07	6.42e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PIK3CA—hematologic cancer	6.03e-07	6.41e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	6.01e-07	6.4e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CG—hematologic cancer	6e-07	6.38e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—IL6—hematologic cancer	6e-07	6.38e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	5.99e-07	6.38e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	5.99e-07	6.37e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AKT1—hematologic cancer	5.98e-07	6.36e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—hematologic cancer	5.94e-07	6.32e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	5.94e-07	6.32e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	5.92e-07	6.3e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	5.92e-07	6.3e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—IL6—hematologic cancer	5.9e-07	6.28e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—AKT1—hematologic cancer	5.86e-07	6.23e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—hematologic cancer	5.85e-07	6.22e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—hematologic cancer	5.84e-07	6.21e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—hematologic cancer	5.82e-07	6.19e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—hematologic cancer	5.8e-07	6.17e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—EP300—hematologic cancer	5.79e-07	6.16e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—hematologic cancer	5.74e-07	6.11e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—hematologic cancer	5.73e-07	6.09e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AKT1—hematologic cancer	5.72e-07	6.08e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AKT1—hematologic cancer	5.69e-07	6.05e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—HRAS—hematologic cancer	5.68e-07	6.05e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—HRAS—hematologic cancer	5.59e-07	5.95e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—HRAS—hematologic cancer	5.58e-07	5.94e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—HRAS—hematologic cancer	5.56e-07	5.92e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CREBBP—hematologic cancer	5.56e-07	5.92e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—HRAS—hematologic cancer	5.55e-07	5.9e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AKT1—hematologic cancer	5.53e-07	5.89e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	5.5e-07	5.85e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—HRAS—hematologic cancer	5.49e-07	5.84e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	5.48e-07	5.83e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AKT1—hematologic cancer	5.44e-07	5.79e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—IL6—hematologic cancer	5.44e-07	5.79e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—AKT1—hematologic cancer	5.37e-07	5.72e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—IL6—hematologic cancer	5.35e-07	5.7e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—IL6—hematologic cancer	5.34e-07	5.68e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—IL6—hematologic cancer	5.32e-07	5.67e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—hematologic cancer	5.32e-07	5.66e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—IL6—hematologic cancer	5.31e-07	5.65e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CD—hematologic cancer	5.27e-07	5.61e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—IL6—hematologic cancer	5.26e-07	5.59e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—IL6—hematologic cancer	5.24e-07	5.58e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ALB—hematologic cancer	5.21e-07	5.54e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	5.09e-07	5.41e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AKT1—hematologic cancer	5.02e-07	5.34e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3R1—hematologic cancer	4.98e-07	5.3e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AKT1—hematologic cancer	4.94e-07	5.25e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AKT1—hematologic cancer	4.93e-07	5.24e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—AKT1—hematologic cancer	4.92e-07	5.24e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AKT1—hematologic cancer	4.91e-07	5.23e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AKT1—hematologic cancer	4.9e-07	5.21e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL6—hematologic cancer	4.87e-07	5.18e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AKT1—hematologic cancer	4.85e-07	5.16e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	4.84e-07	5.15e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CB—hematologic cancer	4.6e-07	4.89e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CA—hematologic cancer	4.55e-07	4.84e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	4.49e-07	4.78e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CA—hematologic cancer	4.29e-07	4.56e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTEN—hematologic cancer	3.97e-07	4.23e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—EP300—hematologic cancer	3.79e-07	4.03e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—AKT1—hematologic cancer	3.72e-07	3.95e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—AKT1—hematologic cancer	3.5e-07	3.73e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CA—hematologic cancer	2.8e-07	2.98e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AKT1—hematologic cancer	2.29e-07	2.44e-06	CbGpPWpGaD
